APG-5918 / Ascentage Pharma  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
APG-5918 / Ascentage Pharma
NCT05415098: Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas

Recruiting
1
90
US
APG-5918
Ascentage Pharma Group Inc.
Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer, Gastric Cancer, Ovarian Clear Cell Carcinoma, Mesothelioma, Sarcoma, Non Hodgkin Lymphoma, B Cell Lymphoma, Epithelioid Sarcoma
09/24
09/25
NCT05773586: A Study to Investigate the Safety, Pharmacokinetics and Efficacy of APG-5918 in Healthy Subjects or Anemic Patients

Recruiting
1
105
RoW
APG-5918, Placebo
Ascentage Pharma Group Inc.
Anemia
08/25
03/26

Download Options